Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-001207-37
    Sponsor's Protocol Code Number:HUB-IDIBELL-SAFO-4.3.1
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2018-07-17
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2018-001207-37
    A.3Full title of the trial
    Phase IV-III Clinical Trial, randomized, controlled, open and multicentric, with parallel groups, to evaluate the efficacy of Cloxacillin and fosfomycin combination versus Cloxacillin monotherapy in the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia.
    Ensayo Clínico de fase IV-III, con asignación aleatoria, controlado, abierto y multicentrico, con grupos paralelos, para evaluar la eficacia de la combinación de Cloxacilina y fosfomicina versus Cloxacilina en monoterapia en el tratamiento de la bacteriemia por Staphylococcus aureus sensible a la Meticilina.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase IV-III Clinical Trial, randomized, controlled, open and multicentric, with parallel groups, to evaluate the efficacy of Cloxacillin and fosfomycin combination versus Cloxacillin monotherapy in the treatment of methicillin-susceptible Staphylococcus aureus bacteraemia.
    Ensayo Clínico de fase IV-III, con asignación aleatoria, controlado, abierto y multicentrico, con grupos paralelos, para evaluar la eficacia de la combinación de Cloxacilina y fosfomicina versus Cloxacilina en monoterapia en el tratamiento de la bacteriemia por Staphylococcus Aureus sensible a la Meticilina
    A.3.2Name or abbreviated title of the trial where available
    HUB-IDIBELL-SAFO-4.3.1
    HUB-IDIBELL-SAFO-4.3.1
    A.4.1Sponsor's protocol code numberHUB-IDIBELL-SAFO-4.3.1
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorMiquel Pujol i Rojo ( Servicio de Enfermedades Infecciosas del Hospital Universitari de Bellvitge
    B.1.3.4CountrySpain
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportFondos de Investigación Sanitarias (FIS) INSTITUTO CARLOS III
    B.4.2CountrySpain
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationMiquel Pujol i Rojo ( Servicio de Enfermedades Infecciosas del Hospital Universitari de Bellvitge
    B.5.2Functional name of contact pointHospital Universitari de Bellvitge
    B.5.3 Address:
    B.5.3.1Street AddressCalle Feixa Llarga, s/n, Planta 17
    B.5.3.2Town/ cityL'Hospitalet de LLobregat (Barcelona)
    B.5.3.3Post code08907
    B.5.3.4CountrySpain
    B.5.4Telephone number34932602487
    B.5.5Fax number34932607274
    B.5.6E-mailmpujol@bellvitgehospital.cat
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCLOXACILINA
    D.3.4Pharmaceutical form Concentrate and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCLOXACILLIN
    D.3.9.1CAS number 61-72-3
    D.3.9.2Current sponsor codeCLOXACILINA
    D.3.9.3Other descriptive nameCLOXACILINA
    D.3.9.4EV Substance CodeSUB06780MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameFOSFOMYCIN
    D.3.2Product code J01XX01
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFOSFOMYCIN
    D.3.9.1CAS number 23155-02-4
    D.3.9.2Current sponsor codeFOSFOMICINA
    D.3.9.3Other descriptive nameFOSFOMICINA
    D.3.9.4EV Substance CodeSUB07797MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationSpain
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCLOXACILLIN
    D.3.4Pharmaceutical form Concentrate and solvent for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCLOXACILLIN
    D.3.9.1CAS number 61-72-3
    D.3.9.2Current sponsor codeCLOXACILINA
    D.3.9.3Other descriptive nameCLOXACILINA
    D.3.9.4EV Substance CodeSUB06780MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Methicilin-susceptible S.aureus bacteraemia.
    Bacteriemia por Staphylococcus aureus sensible a la meticilina
    E.1.1.1Medical condition in easily understood language
    Patients with MSSA bacteraemia.
    Pacientes con bacteriemia por SASM.
    E.1.1.2Therapeutic area Diseases [C] - Bacterial Infections and Mycoses [C01]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10058863
    E.1.2Term Staphylococcus aureus bacteraemia
    E.1.2System Organ Class 100000004862
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    We established two primary object. with hierarchical testing: 1) First primary endpoint: Early success of therapy defined by all of the following criteria met after randomization: - Patient alive at day 7; Clinical success defined as clinical improvement measured by stable or improved quick SOFA score (compared with baseline) AND fever resolved at day 7; Blood cultures negative for S. aureus at day 7. No isolation of S. aureus in another sterile site from day 8 until TOC visit at 12 weeks after random allocation.
    2) Second primary endpoint: Success of therapy is defined at TOC by presence of all of the following (“long time success”): Patient alive at 12 weeks after random allocation; No isolation of S. aureus from sterile site (e.g. blood, joint fluid, tissue) > 14 days from randomization until TOC visit at 12 weeks after random allocation. For both endpoints the use of an additional MSSA-active iv antibiotic until day 7 will be considered as treatment failure (“no success”).
    Se han establecido dos objetivos principales con valoración jerárquica:

    1) Éxito “precoz” del tratamiento (Variable compuesta), definido por cumplir todos los siguientes criterios:
    - Pacientes vivos a los 7 días;
    - Mejoría clínica medida por quick SOFA score y resolución de la fiebre a los 7 días;
    - Negatividad de los hemocultivos a los 7 días;
    - Ausencia de aislamiento de S.aureus de tejidos estériles desde el día 8 hasta 12 semanas desde la asignación aleatoria.

    2) Éxito en la visita final de seguimiento (Test of Cure), definido por cumplir todos los siguientes criterios:
    - Paciente vivo a las 12 semanas desde la asignación aleatoria
    - Ausencia de aislamiento de S.aureus de tejidos estériles desde el día 14 hasta 12 semanas de la asignación aleatoria.

    Por ambos objetivos, la necesidad de cambio de antibióticos durante el periodo del estudio implica la retirada del estudio y será considerado fracaso del tratamiento.
    E.2.2Secondary objectives of the trial
    1)Clinical Obj:All-cause mortality at different visits.Persistent bacteraemia at 3 and 7 days after random allocation.Microbiological relapse as defined by (at least one)positive blood culture for MSSA at least 72h after a preceding negative culture.Complicated bacteraemia.Duration of intravenous antibiotic treatment.Length of stay in hospital.Microbiological secondary endpoints.Pharmacologic secondary endpoints.Sub group analysis for
    patients at high risk.2)Microbiological Obj:To establish duration of bacteraemia,persistent and recurrent bacteraemia.Emergence of fosfomycin resistance.To establish functionality of agr operon and its relationships with changes in vancomycin (VAN) and daptomycin(DAP) MIC and biofilm production.To establish"in vitro"synergy of clox-fos combinations.Sequencing of complete bacterial genome and changes in patients with therapeutic failure3)Pharmacodynamic Obj:To determine the min. and max. concentrations reached in the steady state of free clox. and fos.
    1)Objetivos Clínicos:
    -Mortalidad por cualquier causa en las diferentes visitas
    -Bacteriemia persistente a los 3 y 7 días de la asignación aleatoria
    -Bacteriemia recurrente y complicada
    -Duración del tratamiento antibiótico endovenoso
    -Estancia hospitalaria
    -Objetivos microbiológicos y farmacológicos.
    - Sub-análisis que incluya los pacientes con bacteriemia de alto riesgo
    2) Obj microbiológicos:
    -Establecer la duración de la bacteriemia,bacteriemia persistente y recurrente.
    -Surgimiento de resistencia a fosfomicina.
    -Para establecer la funcionalidad del operón agr y su relación con los cambios en la producción de biocombustibles y vancomicina (VAN) y daptomicina (DAP).
    -Establecer la sinergia "invitro" de combinaciones de cloxacilina-fosfomicina.
    -Secuenciación del genoma bacteriano completo y cambios en pac. con falla terapéutica.
    3)Obj Farmacodinámicos:
    Determinar concentraciones mín. y máx. alcanzadas en el estado estable de cloxacilina libre y fosfomicina.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Pharmacodynamic Obj.:
    To determine the minimum and maximum concentrations reached in the steady state of free cloxacillin and fosfomycin
    Obj Farmacodinámicos:
    Determinar concentraciones mín. y máx. alcanzadas en el estado estable de cloxacilina libre y fosfomicina.
    E.3Principal inclusion criteria
    1) 18 years of age or over.
    2) Patients hospitalised with 1 or more MSSA-positive blood cultures obtained within the 72 hours prior to inclusion in the study, in a context suggesting an infection.
    3) The subject or their legal representative grants informed consent.
    1)Pacientes adultos (18 años o más), de ambos sexos, con bacteriemia por SASM.
    2)Pacientes hospitalizados con 1 o más hemocultivos positivos para SASM obtenidos dentro de las 72 horas previas a la inclusión en el estudio en un contexto sugestivo de infección.
    3)El sujeto o su representante legal otorgan el consentimiento informado.
    E.4Principal exclusion criteria
    1) Compromised clinical situation with a life expectancy of ≤ 24 h.
    2) Resistance to fosfomycin.
    3) Severely impaired liver function (Child-Pugh grade C).
    4) NYHA scale III-IV heart failure.
    5) Need for concomitant antibiotic therapy together with the study antibiotics for the first 7 days of the study, active against S. aureus.
    6) Hypersensitivity to cloxacillin or to beta-lactams in general or to fosfomycin.
    7) Polymicrobial bacteremia.
    8) Participation in another clinical therapy trial.
    9) Previous participation in the present clinical trial.
    10) Myasthenia gravis
    11) Pregnancy and lactation
    1)Situación clínica comprometida con una expectativa de vida ≤ a 24h.
    2) Resistencia a fosfomicina.
    3)Deterioro de la función hepática grave (grado C de Child-Pugh).
    4)Insuficiencia cardíaca escala NYHA III-IV.
    5)Sospecha de endocarditis protésica por SASM (necesidad de tratamiento antibiótico concomitante con actividad frente S. aureus, durante los 7 primeros días del estudio).
    6) Hipersensibilidad a cloxacilina o a beta-lactámicos en general o a fosfomicina.
    7)Bacteriemia polimicrobiana.
    8)Participación en otro ensayo clínico de tratamiento.
    9)Participación previa en el presente ensayo clínico.
    10)Miastenia gravis.
    11)Embarazo y lactancia
    E.5 End points
    E.5.1Primary end point(s)
    Proportion of patients “responders” at day 7 after randomization. Early success of treatment is defined as patients who have completed the study treatment cycle AND without bacteraemia at day 7 AND alive at 7 days AND with clinical improvement at day 7 (qSOFA improvement and resolution of fever) AND without S.aureus isolation from sterile samples from day 8 to 12 weeks after random allocation. Long time success is defined as the proportion of patients "responders" at 12 weeks of having completed the cycle of complete antibiotic treatment (TOC).
    Proporción de pacientes respondedores en la semana 1 (7 días) desde el inicio del tratamiento antibiótico en estudio. También se define como “respondedor” o “éxito del tratamiento” en la semana 1, al paciente que haya completado el ciclo de tratamiento en estudio de 7 días Y sin bacteriemia a los 7 días de haber iniciado el tratamiento en estudio Y que esté vivo a al haber finalizado el ciclo de tratamiento antibiótico de estudio Y que presente mejoría clínica a los 7 días (mejoría quick SOFA score y de la fiebre) Y que no presente aislamiento de S.aureus de tejidos estériles desde el día 8 hasta las 12 semanas desde la asignación aleatoria.
    Proporción de pacientes “respondedores” a las 12 semanas (TOC) desde la asignación aleatoria
    E.5.1.1Timepoint(s) of evaluation of this end point
    The principal endpoint is to demonstrate the effectiveness of the combination of cloxacillin and fosfomycin versus cloxacillin alone in patients with MSSA bacteraemia at 7 days and 12 weeks after random allocation.
    El objetivo principal es demostrar la eficacia de la combinación de cloxacilina y fosfomicina frente a cloxacilina en monoterapia en pacientes con bacteriemia por SASM en la respuesta al tratamiento a los 7 días y a las 12 semanas de la asignación aleatoria.
    E.5.2Secondary end point(s)
    1) Clinical:
    1.1) All-cause mortality at days 7, 14, EOT after random allocation.
    1.2) Number of patients withdrew from the study.
    1.3) Persistent bacteraemia (at least one positive blood culture) at day 3 and at day 7
    1.4) Recurrent bacteraemia during the study period.
    1.5) Patients with persistent and recurrent bacteraemia.
    1.6) Number of patients with complicated bacteraemia
    1.7) Duration of intravenous antibiotic treatment.
    1.8) Length of stay in intensive care unit and in hospital, clinical success at day 3, 7, and the end of the antibiotic study treatment (EOT) and test of cure visit (TOC).
    1.9) Sub group analysis for patients at high risk.

    2)Microbiological:
    2.1) Resistance to fosfomycin during treatment;
    2.2) Minimum inhibitory concentration (MIC) for vancomycin, daptomycin, dalvabancin and its relationship with MSSA complications;
    2.3) Accessory gene regulator (agr) polymorphism;
    2.4) “In vitro” synergy between cloxacillin-fosfomycin;
    2.5) Whole genome sequencing and association of genome changes and patients with therapeutic unsuccessful.

    3) Pharmacokinetics:
    3.1) Minimum concentration (Cmin.),
    3.2) Mid-dosing interval concentration and maximum concentration (Cmax.) reached at the different sampling times.
    3.3) Relationship between PK variables and efficacy.

    4) Security:
    4.1) Incidence of adverse events, serious adverse events, adverse drug reactions, dropouts and its relationship with the study treatment.
    1) Clínicos:

    1.1) Proporción de pacientes fallecidos antes durante el ciclo inicial de tratamiento en estudio (de día 0 a día 7, mortalidad precoz, EOT).
    1.2) Proporción de pacientes fallecidos por cualquier causa durante el periodo de estudio (hasta TOC).
    1.3) Proporción de pacientes que se les tiene que retirar el tratamiento antibiótico en estudio.
    1.4) Proporción de pacientes con bacteriemia persistente al día 3 y al día 7 desde la asignación aleatorización
    1.5) Proporción de pacientes con bacteriemia recurrente en la visita final del seguimiento (TOC). Bacteriemia recurrente: episodio de bacteriemia por SASM >72 horas después de hemocultivos negativos.
    1.6) Proporción de pacientes con bacteriemia persistente y recurrente.
    1.7) Proporción de pacientes con bacteriemia complicada.
    1.8) Valoración de la durada del tratamiento antibiótico endovenoso.
    1.9) Valoración de la durada de la estancia hospitalaria y la proporción de días en una unidad de cuidados intensivos en los dos grupos de tratamiento.
    1.10) Valoración de los objetivos en un sub-análisis que incluya los pacientes con bacteriemia de alto riesgo

    2) Microbiológicos:
    2.1) Proporción de pacientes con resistencia a fosfomicina (emergencia de resistencia a fosfomicina)
    2.2) Proporción de cepas con funcionalidad del operon agr y su relación con alteraciones de la CMI a vancomicina (VAN) y a daptomicina (DAP) y con la producción de biofilm.
    2.3) Asociación de los valores de CMIs a VAN y DAP como marcadores de la aparición de complicaciones en el curso de una bacteriemia por Staphylococcus aureus.
    2.4) Proporción de pacientes con sinergia “in vitro” de las combinaciones de cloxacilina y fosfomicina.
    2.5) Secuenciación del genoma bacteriano completo y proporción de cepas con cambios en su secuencia genética en pacientes con fallo terapéutico.

    3) Farmacocinéticos (PK) / Farmacodinámicos (PD):
    3.1) Concentración mínima (predosis) y concentración máxima alcanzada en estado estacionario de fosfomicina y cloxacilina.
    3.2) Variabilidad farmacocinética de dichas concentraciones
    3.3) Asociación entre las variables de PK y las de eficacia

    4) Criterios de Valoración de la seguridad:
    4.1) Incidencia de acontecimientos adversos según su severidad, gravedad y relación con los tratamientos a estudio.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Secondary variables will be evaluated in different moments depending on each variable definition
    Las variables secundarias se valorarán en diferentes momentos según la definición de cada variable.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    CLOXACILINA
    CLOXACILINA
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned15
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LAST VISIT OF THE LAST SUBJECT (LVLS)
    LA ÚLTIMA VISITA DEL ÚLTIMO PACIENTE
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 150
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 150
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2018-07-17. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    Inclusion criteria included written informed consent signed by patient or legal representant (in case of incapacitation).
    Uno de los criterios de inclusión es la firma del Consentimiento Informado por parte del paciente o de su representante legal.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state366
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After finalization of study treatment cicle, patients will treated following usual clinical practice
    Los pacientes al finalizar el tratamiento del ensayo continuaran tratamiento según práctica clínica habitual.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2019-04-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2019-03-28
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 11:19:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA